Incyte Corporation (INCY)

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will ...

The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Office...

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.

Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.